Bacil Pharma Ltd

Bacil Pharma Annual Report

Bacil Pharma Limited submitted its 39th Annual Report for FY 2025-26. The Annual General Meeting is scheduled for September 23, 2026, via video conferencing.

Bacil Pharma Annual General Meeting

Bacil Pharma Limited has announced book closure dates from September 17 to September 23, 2026, for its 39th Annual General Meeting.

Bacil Pharma Board Meeting Date

Bacil Pharma Limited has scheduled a board meeting for August 29, 2026, to discuss and approve the notice and scheduling of its 39th Annual General Meeting.

Bacil Pharma Board Meeting Outcome

Bacil Pharma Limited announced the appointment of Mr. Mahesh Singh and Mr. Anil Shiv Charan Singh as Additional Directors following its board meeting.

Bacil Pharma Board Meeting Date

Bacil Pharma Ltd has scheduled a Board Meeting for August 25, 2026. The agenda includes the discussion on the appointment of directors.

Bacil Pharma Q1 FY27 Results: Net Profit ₹0.3 Cr, Down 57.1% YoY

Bacil Pharma Ltd reported net profit of ₹0.3 Cr (-57.1% YoY) for Q1 FY27.

Key figure

Net profit ₹0.3 Cr · -57.1% YoY

Bacil Pharma Board Meeting Date

Bacil Pharma Limited has scheduled a board meeting for August 12, 2026, to consider and approve the unaudited financial results for the quarter ending June 30, 2026.

Bacil Pharma Other Announcement

Bacil Pharma Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ending September 30, 2025.

Bacil Pharma Merger & Restructuring

Bacil Pharma Limited has incorporated a wholly-owned subsidiary named BACIL RESEARCH & DEVELOPMENT PRIVATE LIMITED. This strategic move expands the company's corporate structure.

Bacil Pharma Other Announcement

Bacil Pharma Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with regulatory disclosure requirements.

Bacil Pharma Fund Raise of ₹50 Cr

Bacil Pharma approved a Rights Issue of up to ₹50 Crore to raise funds. The Board also noted the resignation of two Independent Directors.

Value

₹50.00 Cr

Bacil Pharma Board Meeting Outcome

Bacil Pharma Ltd’s board approved a ₹50 Crore rights issue and increased authorized capital by ₹45 Crore. It also accepted the resignations of two independent directors.

Value

₹50.00 Cr

Bacil Pharma Fund Raise of ₹50 Cr

Bacil Pharma's board approved a Rs. 50 Crore fundraise via Rights Issue. The board also increased authorized share capital and accepted resignations of two independent directors.

Value

₹50.00 Cr

Bacil Pharma Merger & Restructuring

Bacil Pharma Ltd received approval for the name of its proposed wholly-owned subsidiary. Incorporation is underway, pending final Certificate of Incorporation.